Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-GAP: Intermittent vs Continuous Anti-PD-1 Therapy in Metastatic Melanoma
NCT02821013Phase 3Recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Oct 2016
- Primary completion
- Dec 2027
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in melanoma (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Overall survival at 7 years. Started Oct 2016; status: recruiting.
02
Conditions
melanoma
Beyond the preview
Go deeper on NCT02821013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02821013.